Tau Protein Degrader
-
QC-01–175
0 ImagesQC-01-175 is a Tau PROTAC degrader, with Kd values of 1.2 μM, 1.7 μM and 2.5 μM for wild-type, A152T mutant and P301L mutant tau-441 proteins, respectively. QC-01-175 binds to both Tau and CRBN, triggering ubiquitination and proteasomal degradation of Tau. QC-01-175 preferentially targets disease-associated Tau proteins in frontotemporal dementia. QC-01-175 inhibits MAO activity, with an IC50 of 8.56 μM. QC-01-175 suppresses the elevation of ROS levels. QC-01-175 can be used in studies related to frontotemporal dementia and amyotrophic lateral sclerosis.
-
C004019
0 ImagesC004019 is a BBB-penetrable and small-molecule PROTAC that targets tau. C004019 can simultaneously recruit tau and E3 ligase, and effectively clear tau proteins by promoting the ubiquitination and proteasome-dependent degradation of tau, thereby improving synaptic and cognitive functions in Alzheimer's disease (AD) mice. C004019 can be used in the research of AD and tau protein-related diseases.
-
PROTAC α-Synuclein/Tau degrader 1
0 ImagesPROTAC α-Synuclein/Tau degrader 1 is a blood-brain barrier-penetrant dual PROTAC degrader of α-synuclein (α-Syn) and tau, with DC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 binds to α-Syn and tau PFF, with KDs of 0.47 and 2.78 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 exhibits degradation effect mediated by the ubiquitin-proteasome system (UPS). PROTAC α-Synuclein/Tau degrader 6 can be used for the study of Parkinson’s disease (PD) (Pink: α-Synuclein/Tau ligand (HY-151035); Blue: CRBN ligase ligand (HY-14658); Black: Linker (HY-128803)).
-
MRL828
0 ImagesCat. No.: HY-176130CAS No.: 3115333-82-6MRL828 is a heterobifunctional molecule that targets aggregated tau protein. As an autophagy-targeting chimera (ATTEC), MRL828 selectively labels aggregated tau protein for clearance via the autophagy (autophagy)-lysosome pathway. The activity of MRL828 depends on autophagosomes rather than lysosomes, and it induces autophagosome-dependent secretion. MRL828 acts as an intracellular aggregate inhibitor and a secretory autophagy inducer, reducing intracellular levels of aggregated tau protein through autophagosome-dependent secretory autophagy instead of lysosomal degradation. MRL828 can be used in the research of neurodegenerative diseases such as Alzheimer's disease.
